

20 February 2023

ASX Release

**Oventus Medical Ltd
(In Liquidation)
ACN 608 393 282 ('Company' or 'Oventus Medical')**

Market update – Sale of Oventus Manufacturing Pty Ltd

We refer to the appointment on 14 June 2022 of Michael McCann and Graham Killer of Grant Thornton as Administrators (**Administrators**) of Oventus Medical, Oventus Manufacturing Pty Ltd (Subject to Deed of Company Arrangement) ACN 163 851 287 (**Oventus Manufacturing**) and Oventus CRM Pty Ltd (In Liquidation) ACN 608 397 726 (**Oventus CRM**).

The Administrators refer to the ASX Announcement dated 14 February 2023.

Oventus Medical has completed the sale of 100% of the issued share capital in Oventus Manufacturing to Crystalaid Manufacture Pty Ltd. As referenced in the ASX Announcement, the shares in Oventus Manufacturing were sold on an "as is where is" basis with no warranties and were sold for \$10,000, with Crystalaid making a contribution to a Deed Fund under the DOCA in the amount of \$430,000.

Shareholder Questions

For further information in relation to the external administration of Oventus or the information set out above, the contact details of the Administrators are given below:
Email: Oventus@au.gt.com

ENDS –

This announcement has been approved for lodgement by the Administrators.

While Oventus remains admitted to the ASX, the Administrators will continue to provide updates to shareholders over the course of the administration by way of announcements to the ASX.

